Montelukast therapy and psychological distress in chronic obstructive pulmonary disease (COPD): a preliminary report

Arch Gerontol Geriatr. 2011 Jan-Feb;52(1):e36-9. doi: 10.1016/j.archger.2010.04.014. Epub 2010 May 15.

Abstract

Chronic obstructive pulmonary disease (COPD) is an alteration in which ventilatory function, exercise capacity and health status of patients progressively decline and it is characterized by an increase of inflammatory cytokines such as TNF-α, LTB4, IL-8, etc. In this study we considered twenty patients (15 males and 5 females; mean age: 72.8 ± 6.3) with stable COPD. All patients were performed evaluation of psychological stress at enrollment and were treated with leukotriene receptor antagonists (montelukast tablets) 10mg/day for 12 months. After 12 months we observed a significant decrease of serum levels of LTB4, IL-8 and also a decrease of the number of outpatient clinic visits, of the number of hospitalizations and of the duration of hospitalization.

Publication types

  • Clinical Trial

MeSH terms

  • Acetates / therapeutic use*
  • Aged
  • Anti-Asthmatic Agents / therapeutic use*
  • Cyclopropanes
  • Female
  • Hospitalization / statistics & numerical data
  • Humans
  • Interleukin-8 / blood
  • Leukotriene B4 / blood
  • Male
  • Pulmonary Disease, Chronic Obstructive / blood
  • Pulmonary Disease, Chronic Obstructive / drug therapy
  • Pulmonary Disease, Chronic Obstructive / psychology*
  • Quinolines / therapeutic use*
  • Stress, Psychological / etiology*
  • Sulfides
  • Tumor Necrosis Factor-alpha / blood

Substances

  • Acetates
  • Anti-Asthmatic Agents
  • Cyclopropanes
  • Interleukin-8
  • Quinolines
  • Sulfides
  • Tumor Necrosis Factor-alpha
  • Leukotriene B4
  • montelukast